Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
1(8%)
Results Posted
20%(2 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
4
33%
Ph not_applicable
1
8%
Ph early_phase_1
1
8%
Ph phase_2
3
25%
Ph phase_4
2
17%
Ph phase_3
1
8%

Phase Distribution

5

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
4(33.3%)
Phase 2Efficacy & side effects
3(25.0%)
Phase 3Large-scale testing
1(8.3%)
Phase 4Post-market surveillance
2(16.7%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(10)
Terminated(1)

Detailed Status

Completed10
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (8.3%)
Phase 14 (33.3%)
Phase 23 (25.0%)
Phase 31 (8.3%)
Phase 42 (16.7%)
N/A1 (8.3%)

Trials by Status

terminated18%
completed1083%
recruiting18%

Recent Activity

1 active trials
Showing 5 of 12
recruitingphase_2

NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

NCT04750616
terminatednot_applicable

Low Dose Niacin (Vitamin B3) for Parkinson's Disease

NCT03808961
completedphase_1

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

NCT00691210
completedphase_2

Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)

NCT02558595
completedphase_1

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

NCT01381354
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04750616Phase 2

NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

Recruiting
NCT03808961Not Applicable

Low Dose Niacin (Vitamin B3) for Parkinson's Disease

Terminated
NCT00691210Phase 1

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

Completed
NCT02558595Phase 2

Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)

Completed
NCT01381354Phase 1

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

Completed
NCT03392623Early Phase 1

DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide.

Completed
NCT02140814Phase 2

Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease

Completed
NCT00033436Phase 3

Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer

Completed
NCT01542138Phase 4

Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation

Completed
NCT00140166Phase 4

Treatment of Acute Schizophrenia With Vitamin Therapy

Completed
NCT00316472Phase 1

The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients

Completed
NCT00508885Phase 1

The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12